United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHRGet Rating) CEO Martine A. Rothblatt sold 8,000 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $263.97, for a total value of $2,111,760.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $34,316.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Up 0.4 %

Shares of NASDAQ UTHR opened at $265.59 on Tuesday. United Therapeutics Co. has a one year low of $158.38 and a one year high of $270.61. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The business’s fifty day moving average price is $228.55 and its 200-day moving average price is $224.37. The stock has a market capitalization of $12.10 billion, a PE ratio of 18.07, a P/E/G ratio of 1.77 and a beta of 0.59.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Bank of America reiterated an “underperform” rating on shares of United Therapeutics in a report on Tuesday, September 20th. Wedbush upped their price objective on United Therapeutics from $250.00 to $305.00 in a research note on Thursday, November 3rd. Oppenheimer upped their price objective on United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, November 3rd. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $282.75.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in United Therapeutics by 205.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 641,656 shares of the biotechnology company’s stock worth $151,200,000 after purchasing an additional 431,739 shares in the last quarter. Deutsche Bank AG lifted its holdings in United Therapeutics by 1,011.5% during the 2nd quarter. Deutsche Bank AG now owns 196,876 shares of the biotechnology company’s stock worth $46,393,000 after purchasing an additional 179,163 shares in the last quarter. Vanguard Group Inc. lifted its holdings in United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company’s stock worth $923,703,000 after purchasing an additional 163,542 shares in the last quarter. Finally, Farallon Capital Management LLC lifted its holdings in United Therapeutics by 40.0% during the 3rd quarter. Farallon Capital Management LLC now owns 549,673 shares of the biotechnology company’s stock worth $115,091,000 after purchasing an additional 156,977 shares in the last quarter. Hedge funds and other institutional investors own 95.57% of the company’s stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.